Biosimiliar Research Grade Antibodies
In Vivo Functional Grade Biosimiliars
Range of research-grade biosimiliar antibodies including Adalimumab, Nivolumab & more
What are Research-Grade Biosimiliar Antibodies?
Therapeutic antibodies are used to treat autoimmune diseases and cancer. These antibodies however are difficult to source and expensive which can impede research. Assay Genie's Research-Grade Biosimiliar Antibodies are produced by recombinant technology incorporating the variable region of therapeutic monoclonal antibodies which results in biologics of the same specificity. Our biosimiliar antibodies can be used for research applications such as flow cytometry, functional assays, IHC, immunoprecipitation, ELISA and western blotting among others. Our range of biosimiliars are ultra-pure with very low-endotoxin levels and free from preservatives and stabilisers
Research-Grade Biosimiliar Antibodies: Key Features
| Low-Endotoxin | Our in vivo antibodies have the highest quality standards with low endotoxin levels and no detectable leachable protein A or aggregates. | |
| High Purity | Purified by a multi-step process and are subjected to extensive QC to ensure high reproducibility between lots. | |
| Formulation | No preservatives, stabilisers or carrier protein. Sterile PBS free from K+ or Ca2+. | |
| Comprehensive | 200+ functional-grade antibodies for research use. |
Range of Biosimiliar Antibodies
| Product Name | Clone | Reactivity | Application |
| Anti-Adalimumab (TNF alpha) Antibody | AFS98 | Human | B, ELISA, FA, FC, IF, IHC, IP, N |
| Anti-Mogamulizumab (CD194 / CCR4) Antibody | AFS98 | Human | Depletion, ELISA, FA, FC |
| Anti-Mogamulizumab (CD194 / CCR4) Antibody (Fc Reduced) | MP4-25D2 | Human | Depletion, ELISA, FA, FC |
| Anti-Adalimumab (TNF alpha) Antibody (Fc Reduced) | MAR1-5A3 | Human | B, ELISA, FA, FC, IF, IHC, IP, N |
| Anti-Natalizumab (CD49D / Integrin alpha 4) Antibody | ALF-161 | Human | B, FC |
| Anti-Natalizumab (CD49D / Integrin alpha 4) Antibody (Fc Reduced) | JAMA-147 | Human | B, FC |
| Anti-Nivolumab (CD279 / PD-1) Antibody | TN3-19.12 | Human/Cynomolgus Monkey | B, FA, FC, IHC |
| Anti-Nivolumab (CD279 / PD-1) Antibody (Fc Reduced) | TN3-19.12 | Human/Cynomolgus Monkey | B, FA, FC, IHC |
| Anti-Oxelumab (OX40L) Antibody | Y-3 | Human | B, FA, FC |
| Anti-Oxelumab (OX40L) Antibody (Fc Reduced) | Y-3 | Human | B, FA, FC |
| Anti-Tabalumab (CD257 / BAFF) Antibody | 7G7B6 | Human/Cynomolgus Monkey/Rabbit | ELISA, FA, FC, IF, IP, N, WB |
| Anti-Tabalumab (CD257 / BAFF) Antibody (Fc Reduced) | OKT-4 | Human/Cynomolgus Monkey/Rabbit | ELISA, FA, FC, IF, IP, N, WB |
| Anti-Trastuzumab (HER-2) Antibody | G28.5 | Human | CyTOF, ELISA, FC, IHC |
| Anti-Trastuzumab (HER-2) Antibody (Fc Reduced) | W6/32 | Human | CyTOF, ELISA, FC, IHC |
| Anti-Ipilimumab (CTLA-4) Antibody | W6/32 | Human | B, CyTOF, ELISA, FC |
| Anti-Ipilimumab (CTLA-4) Antibody (Fc Reduced) | T56/14 | Human | B, CyTOF, ELISA, FC |
| Anti-Sarilumab (IL-6) Antibody | T56/14 | Human | B, ELISA, FA, FC, IHC, N, WB |
| Anti-Sarilumab (IL-6) Antibody (Fc Reduced) | 2H7 | Human | B, ELISA, FA, FC, IHC, N, WB |
| Anti-SARS-CoV-2 Spike RBD [2165] | 2H7 | SARS-CoV-2 ⋅ Virus | ELISA, IHC, N |
| Anti-SARS-CoV-2 Spike RBD [2165] - Biotin | L243 | SARS-CoV-2 ⋅ Virus | ELISA, IHC |
| Anti-SARS-CoV-2 Spike RBD [2165] - HRP | L243 | SARS-CoV-2 ⋅ Virus | ELISA, IHC |
| Anti-Alemtuzumab (CD52) Antibody | XMG1.2 | Human/Rhesus Monkey/Cynomolgus Monkey | CyTOF, ELISA, FA, FC, IHC FF, IHC FFPE, WB |
| Anti-SARS-CoV-2 Spike NTD [2146] | C17.8 | SARS-CoV-2 ⋅ Virus | ELISA, IHC |
| Anti-SARS-CoV-2 Spike NTD [2146] - Biotin | JES6-1A12 | SARS-CoV-2 ⋅ Virus | ELISA, IHC |
| Anti-SARS-CoV-2 Spike NTD [2146] - HRP | 1A8 | SARS-CoV-2 ⋅ Virus | ELISA, IHC |
| Anti-Alemtuzumab (CD52) Antibody (Fc Reduced) | 1A8 | Human/Rhesus Monkey/Cynomolgus Monkey | CyTOF, ELISA, FA, FC, IHC FF, IHC FFPE, WB |
| Anti-Basiliximab (IL-2R alpha / CD25) Antibody | 2.4G2 | Human/Rhesus Monkey/Cynomolgus Monkey | B, CyTOF, FC, IF, IHC, WB |
| Anti-SARS-CoV-2 Spike RBD [2838] | 2.4G2 | SARS-CoV-2 ⋅ Virus | ELISA |
| Anti-Basiliximab (IL-2R alpha / CD25) Antibody (Fc Reduced) | P84 | Human/Rhesus Monkey/Cynomolgus Monkey | B, CyTOF, FC, IF, IHC, WB |
| Anti-Bevacizumab (VEGF) Antibody | P84 | Human | B, ELISA, FC, IP, N, WB |
| Anti-SARS-CoV-2 Spike RBD [2381] | 29F.1A12 | SARS-CoV-2 ⋅ Virus | ELISA |
| Anti-Bevacizumab (VEGF) Antibody (Fc Reduced) | 29F.1A12 | Human | B, ELISA, FC, IP, N, WB |
| Anti-Briakinumab (IL 12/23) Antibody | H22 | Human | B, ELISA, FA, FC, IF, IP, N, WB |
| Anti-SARS-CoV-2 Spike RBD [2355] | H22 | SARS-CoV-2 ⋅ Virus | ELISA, N |
| Anti-Briakinumab (IL 12/23) Antibody (Fc Reduced) | UC7-13D5 | Human | B, ELISA, FA, FC, IF, IP, N, WB |
| Anti-Cetuximab (EGFR) Antibody | UC7-13D5 | Human | B, CyTOF, ELISA, FC, ICC, IHC |
| Anti-SARS-CoV-2 Spike NTD [2215] | RMP1-14 | SARS-CoV-2 ⋅ Virus | ELISA |
| Anti-Cetuximab (EGFR) Antibody (Fc Reduced) | RMP1-14 | Human | B, CyTOF, FC |
| Anti-SARS-CoV-2 Nucleocapsid (N) | TY25 | SARS-CoV-2 ⋅ Virus | ELISA, IHC, WB |
| Anti-Rituximab (CD20) Antibody | FD441.8 | Human/Rhesus Monkey/Cynomolgus Monkey | FC |
| Anti-Rituximab (CD20) Antibody (Fc Reduced) | FD441.8 | Human/Rhesus Monkey/Cynomolgus Monkey | FC |
| Anti-Human NRG1-β1 - Biotin | M1/70 | Human | ELISA Det, WB |